Premature Infants Clinical Trial
Official title:
Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage
Erythropoietin (EPO) has been shown to be neurotrophic and neuroprotective in several animal models and some clinical studies. Our hypothesis is that EPO could improve long-term neurological outcomes in very preterm infants with intraventricular hemorrhage (IVH). The aim of this study is to evaluate the long-term neuroprotective effect of repeated low-dose EPO (500 U/kg) in very preterm infants with IVH.
IVH is one of the most common complications in preterm infants. Nearly 60% of preterm infants with grade III-IV IVH develop severe neurodevelopmental outcomes. There are currently no effective treatments to prevent preterm infants with IVH from developing ventricular dilation or serious neurological disabilities. Recent studies have shown that EPO could improve neurodevelopmental outcomes in preterm infants with grade III-IV IVH. However, the dose and course of EPO in preterm infants is still uncertain. The purpose of the study was whether repeated low-dose EPO (500 U/kg, every other day, for 2 weeks) given to very preterm right after the diagnosis of IVH could improve long-term neurological outcomes. Very preterm infants with gestational age of ≤ 32 weeks who are diagnosed with IVH within 72 hours after birth in NICU are eligible for enrolment. After informed consent is obtained, infants will be randomly assigned to EPO group or vehicle group. The primary outcome is whether EPO improves mortality and neurological disabilities in very preterm infants with IVH at 18 months of corrected age, and the secondary outcome was whether EPO decrease the incidence of cerebral palsy, MDI<70, blindness, and deafness. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02785926 -
Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates
|
||
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Completed |
NCT01530360 -
Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants
|
Phase 1 | |
Completed |
NCT00681018 -
Feeding Study in Premature Infants
|
N/A | |
Completed |
NCT00217191 -
Ibuprofen and Renal Function in Premature Infants
|
Phase 4 | |
Completed |
NCT01077271 -
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
|
N/A | |
Completed |
NCT00282113 -
Effects of Probiotic and Prebiotic Combinations on Premature Infants
|
N/A | |
Active, not recruiting |
NCT02943746 -
Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants
|
N/A | |
Completed |
NCT01994954 -
A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants
|
N/A | |
Completed |
NCT00389909 -
Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants
|
Phase 4 | |
Completed |
NCT00747591 -
Urine Concentration of S100B in Extremely Premature Infants
|
N/A | |
Recruiting |
NCT04555590 -
Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants
|
N/A | |
Completed |
NCT06352047 -
The Effects of Positioning After Extubation of Preterm Infants on the Respiratory Functions
|
N/A | |
Completed |
NCT03217045 -
Nutrition Protocol and Premature Infants' Growth
|
||
Recruiting |
NCT03552952 -
Development of Preterm Infant Gut Microbiome
|
||
Recruiting |
NCT06332521 -
Infant Crying, a Bioacoustic Prognostic Signal for Neurodevelopment
|
||
Completed |
NCT04659083 -
How NAVA Works in Preterm Infants With Irregular Respiratory Efforts
|
||
Completed |
NCT05807191 -
The Effect of Using Clinical Guidelines on Kangaroo Care on Newborn and Maternal Outcomes
|
N/A | |
Completed |
NCT01140243 -
Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital
|
N/A | |
Completed |
NCT00957840 -
Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome
|
N/A |